Business Wire

Allison Unveils New Brand Identity to Reflect Agency’s Evolution

6.9.2023 13:00:00 EEST | Business Wire | Press release

Share

After more than two decades of remarkable growth and evolution, Allison (fka Allison+Partners) is excited to unveil its new brand identity, complete with a new name, logo, website and visual identity. The rebranding effort reflects the agency's transformation from its origin as a traditional PR firm focused on earned media to a modern integrated marketing and communications powerhouse with a global presence.

"Today marks a significant milestone in our history,” says Scott Allison, global chairman and CEO of Allison. “The unveiling of our new brand identity represents not just a change in name and logo, but a bold declaration of our commitment to shaping the future of integrated marketing and communications. We have evolved alongside the industry, embracing innovation and expanding our global footprint. This rebranding is a testament to our team's dedication to excellence, creativity, and the relentless pursuit of solutions that drive meaningful impact for our clients. With Allison, we are poised to lead the way in a new era of communications."

Why Rebrand? Why Now?

Over the past 22 years, Allison has undergone a remarkable evolution, expanding its services, client portfolio and talent base to encompass a diverse range of expertise, from to creative solutions. The agency also saw significant growth in the number of global assignments —with seven of its top 10 clients now represented across multiple markets—and an enhanced client roster of global brands, such as AB InBev, GE Appliances, Hewlett Packard Enterprise, IHG, Kyndryl and Revlon. This rebranding initiative is a response to the need for a refreshed brand identity that aligns with the agency's current and future trajectory, while highlighting its unique culture, global reach, integrated capabilities and forward-thinking approach. Visit the new website at www.allisonworldwide.com to explore the refreshed brand identity and learn more about Allison's innovative solutions.

Solving Fragmentation and Embracing Innovation

The rebranding also aims to address the challenge of fragmentation that has naturally occurred as the agency has grown and the marketing landscape has evolved, potentially diluting or blurring the agency's points of differentiation. By simplifying and unifying the brand story, Allison will better convey its ability to solve complex business challenges, attract top talent, and provide integrated marketing and communications on a global scale. The new brand identity not only celebrates the agency's growth but also positions it as a driver of the industry's future innovations.

A Fresh and Modern Identity Built In-House

Allison’s Brand and Engagement Strategy Team led the new brand identity, using its approach to research, strategy and branding for clients called V.I.T.A.L, which is a framework that helps companies understand and express a brand’s humanity (and therefore build engagement). The new brand features a sleek and modern logo that signifies the agency's evolution and commitment to innovation. The cutout in the I represent the agency’s vision of always moving forward with innovation and a commitment to excellence. The name change to "Allison" showcases a more inclusive and contemporary identity, while paying homage to the agency's founders and their values. The removal of "+Partners" reflects the team-oriented approach Allison has always been known for, emphasizing the agency's focus on inclusion, unity and diversity.

Forward-Looking Vision

With the rebrand, Allison sets its sights on its evolution to a fully integrated marketing and communications consultancy. Its Marketing Innovation Team offers integrated marketing, brand engagement strategies, performance marketing, creative, Storytelling Studio, and research and analytics functions, while its Allison Advisory team helps the C-suite accelerate growth by finding and optimizing the intersection of business goals, customer needs, regulatory environments and employee experience. The agency plans to bolster its creative capabilities, achieve rapid growth through targeted acquisitions, and continue to expand its service offerings beyond its PR roots driving innovation through a deep expertise in data and technology.

Brand Manifesto, Mission, Vision, and Purpose

The new brand manifesto, Always Forward, speaks to the agency's dedication to agility, innovation and forward momentum. The mission underscores that it's all about the work—unlocking insights, inspiring innovation and building meaningful connections. The vision and purpose highlight Allison's commitment to a limitless environment where everyone can build, create and grow, while using creativity to drive positive change and business success.

Agency Solutions

At the heart of the rebrand is a profound shift towards enhanced client offerings. Every solution is thoughtfully crafted to address the unique challenges our clients face in today's ever-changing global marketplace. By immersing ourselves in our clients' issues, Allison transcends the boundaries of conventional marketing, emerging as problem solvers and trusted partners. With this new approach, Allison emphasizes its ability to drive awareness and demand, increase cultural relevance, build and protect reputations, transform brands, and elevate business performance for clients across the globe. The solutions are not just services; they are pathways to success, strategies to create change and blueprints for navigating the dynamic marketing landscape.

With this rebrand, Allison is poised to embark on an exciting new chapter, while respecting the legacy of growth that has made it one of the greatest success stories in the industry over the past 22 years, showcasing its evolution, innovation and commitment to always move forward. The new brand identity captures the agency's spirit and dedication, ensuring it remains at the forefront of the industry for years to come.

About Allison

Allison is a global integrated marketing and communications consultancy, dedicated to driving growth, innovation, and positive change for clients, colleagues, and communities. With a diverse range of expertise and a forward-looking mindset, Allison delivers game-changing results that make a lasting impact. Allison is owned by Stagwell (NASDAQ: STGW), one of the fastest growing and most influential marketing and communications networks in the world. Agency partners leverage Stagwell’s technology, data analytics, insights and strategic consulting solutions to drive measurable results and optimize return on marketing investment for more than 1,700 clients worldwide. Learn more at www.allisonworldwide.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For media inquiries:

Shanna Brown
Shanna.Brown@allisonworldwide.com
646.428.6837

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye